NCT02068222View on ClinicalTrials.gov

A Study to Evaluate the Safety and Antiviral Effect of ABT-450/Ritonavir and ABT-530 Coadministered With and Without Ribavirin in Adults With Genotype 3 Hepatitis C (HCV) Infection

PHASE2CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

April 30, 2014

Primary Completion Date

March 31, 2015

Study Completion Date

March 31, 2015

Conditions
Chronic Hepatitis CHepatitis C Virus
Interventions
DRUG

ABT-450/ritonavir (r)

Tablet

DRUG

ABT-530

Tablet

DRUG

Ribavirin (RBV)

Tablet

Sponsors

Lead Sponsor

AbbVie
All Listed Sponsors
lead

AbbVie

INDUSTRY

NCT02068222 - A Study to Evaluate the Safety and Antiviral Effect of ABT-450/Ritonavir and ABT-530 Coadministered With and Without Ribavirin in Adults With Genotype 3 Hepatitis C (HCV) Infection | Biotech Hunter | Biotech Hunter